Brokerages predict that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report earnings of ($1.27) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Alnylam Pharmaceuticals’ earnings. The highest EPS estimate is ($1.10) and the lowest is ($1.36). Alnylam Pharmaceuticals reported earnings of ($1.05) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 21%. The business is scheduled to issue its next earnings report on Friday, May 5th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($5.19) per share for the current fiscal year, with EPS estimates ranging from ($6.04) to ($4.16). For the next year, analysts expect that the firm will post earnings of ($4.79) per share, with EPS estimates ranging from ($5.94) to ($3.03). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.02. The business earned $19 million during the quarter, compared to analyst estimates of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The company’s quarterly revenue was up 160.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.21) earnings per share.
ALNY has been the subject of a number of research reports. Chardan Capital raised their target price on Alnylam Pharmaceuticals from $69.00 to $97.00 and gave the company a “buy” rating in a research note on Monday, January 9th. Vetr lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $46.27 target price for the company. in a research note on Wednesday, January 11th. Ladenburg Thalmann Financial Services initiated coverage on Alnylam Pharmaceuticals in a research note on Thursday, February 2nd. They issued a “buy” rating and a $75.00 target price for the company. JMP Securities set a $69.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, February 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $68.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 9th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $64.87.
Institutional investors have recently modified their holdings of the company. Mn Services Vermogensbeheer B.V. boosted its position in shares of Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 87 shares during the period. First Manhattan Co. bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $135,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $148,000. Hall Laurie J Trustee bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $160,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $205,000. Hedge funds and other institutional investors own 88.70% of the company’s stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 0.36% during trading on Monday, hitting $55.07. 1,026,373 shares of the stock traded hands. The stock’s market cap is $4.74 billion. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $80.11. The company has a 50-day moving average price of $51.86 and a 200 day moving average price of $45.21.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com